预约演示

BMS reports positive three-year results for Opdivo to treat bladder cancer

2023-02-21

临床结果临床3期上市批准

Bristol Myers Squibb (BMS) has reported positive three-year follow-up results from its phase 3 trial of Opdivo (nivolumab) in certain patients with urothelial carcinoma, the most common type of bladder cancer.

Bristol Myers Squibb, which most frequently begins in the cells that line the inside of the bladder, accOpdivo (nivolumab)ately 90% of bladder canceurothelial carcinoma bladder cancer

Urothelial carcinomahelial carcinomas are diagnosed at an early stage, but rates of recurrence and disease progression are high and arobladder cancerients who undergo radical surgery will experience disease recurrence.

The latest resulurothelial carcinomase-274 trial demonstrate significant sustained clinical benefits with Opdivo for the adjuvant treatment of patients with muscle-invasive urothelial carcinoma at a high risk of recurrence after radical resection.

At a median follow-up of 36.1 months, Opdivo more than doubled the average length of time patients lived wOpdivo disease recurrence, demonstrating a median dmuscle-invasive urothelial carcinomampared to 10.9 months with placebo.

Additionally, those treated with OpdivOpdivoed a median non-urothelial tract recurrence-free survival (NUTRFS) of 25.9 months compared to 13.7 months for placebo and, in patients whose tumour cells expressed PD-L1 of 1% and over, median NUTRFS was 52.6 months with Opdivo versus 8.4 months with placebo.

Benefits were also seen across exOpdivoory endpoints, including distant metastasis-free survival and second progression-free survival (defined as the time from randomisation to disease tumourssion after subsePD-L1 next-line systemic therapy, start of second subsequOpdivoxt-line systemic therapy or death).

Dana Walker, vice president, development programme lead, genitourinary cancers at BMS, said: “The durable follow-up results from CheckMate -274 continue to fuel our excitement toward our ongoing research in earlier stages and its potential to change outcomes for patients.

“We look forward to closely following the CheckMate -274 genitourinary cancersng to assess additional key secondary endpoints, including overall survival to which we currently remain blinded.”

Opdivo is currently approved in more than 65 countries, including the US, EU, Japan and China for a range of indications such as melanoma, lung, kidney and gastric cancers.

Opdivoember 2022, the drug was recommended by the National Institute of Health and Care Excellence (NICE) as a first-line treatmemelanomagside chemotherapy, for rare forms of advanced gastroesophageal cancer.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构